Is Mirum Pharmaceuticals About to Soar in 2026?
2026-01-27 03:15:00 ET
Mirum Pharmaceuticals ' (NASDAQ: MIRM) share price has more than doubled over the last 12 months. Is this biotech stock about to soar again in 2026? I think so – for two key reasons.
In several important ways, Mirum is at an inflection point. It achieved positive cash flow from operations in 2025. That's a significant milestone for any small biotech company.
Mirum won two approvals from the U.S. Food and Drug Administration (FDA) last year. In February, the agency gave Ctexli a thumbs-up for the treatment of cerebrotendinous xanthomatosis (CTX), a rare genetic disorder of bile acid synthesis. The FDA also approved a tablet formulation of Livmarli in April for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC), both rare liver diseases.
NASDAQ: MIRM
MIRM Trading
1.3% G/L:
$90.695 Last:
250,112 Volume:
$89.85 Open:
